简介内容:YF135, a reversible-covalent KRAS G12C PROTAC, effectively induces the degradation of KRAS G12C and reduces phospho-ERK levels via the E3 ligase VHL-mediated proteasome pathway. Designed by integrating the KRAS G12C inhibitor 48 (compound 6d) as the ligand, YF135 utilizes the MRTX849 linkage VHL ligand scaffold.